A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification

被引:18
|
作者
Bamborough, Paul [1 ]
Chung, Chun-wa [1 ]
Demont, Emmanuel H. [1 ]
Bridges, Angela M. [1 ]
Craggs, Peter D. [1 ]
Dixon, David P. [1 ]
Francis, Peter [1 ]
Furze, Rebecca C. [2 ]
Grandi, Paola [3 ]
Jones, Emma J. [1 ]
Karamshi, Bhumika [1 ]
Locke, Kelly [1 ]
Lucas, Simon C. C. [1 ]
Michon, Anne-Marie [3 ]
Mitchell, Darren J. [1 ]
Pogany, Peter [1 ]
Prinjha, Rab K. [2 ]
Rau, Christina [3 ]
Maria Roa, Ana [4 ]
Roberts, Andrew D. [1 ]
Sheppard, Robert J. [2 ,5 ]
Watson, Robert J. [1 ]
机构
[1] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Med Sci & Technol, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline Res & Dev Ltd, Med Res Ctr, Epigenet Res Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England
[3] Cellzome, Meyerhofstr 1, D-69117 Heidelberg, Germany
[4] GlaxoSmithKline Tres Cantos, Madrid 28760, Spain
[5] AstraZeneca, Med Chem Cardiovasc Renal & Metab Dis, IMED Biotech Unit, S-43150 Gothenburg, Sweden
关键词
DRUG DISCOVERY; HALOGEN BONDS; RECOGNITION; CANCER; ANCCA; CHEMISTRY; PROTEIN; COACTIVATOR; BIOPHYSICS; BREAST;
D O I
10.1021/acs.jmedchem.9b00673
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The bromodomain of ATAD2 has proved to be one of the least-tractable proteins within this target class. Here, we describe the discovery of a new class of inhibitors by high-throughput screening and show how the difficulties encountered in establishing a screening triage capable of finding progressible hits were overcome by data-driven optimization. Despite the prevalence of nonspecific hits and an exceptionally low progressible hit rate (0.001%), our optimized hit qualification strategy employing orthogonal biophysical methods enabled us to identify a single active series. The compounds have a novel ATAD2 binding mode with noncanonical features including the displacement of all conserved water molecules within the active site and a halogen-bonding interaction. In addition to reporting this new series and preliminary structure-activity relationship, we demonstrate the value of diversity screening to complement the knowledge-based approach used in our previous ATAD2 work. We also exemplify tactics that can increase the chance of success when seeking new chemical starting points for novel and less tractable targets.
引用
收藏
页码:7506 / 7525
页数:20
相关论文
共 38 条
  • [1] Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening
    Yao, Dahong
    Zhang, Jin
    Wang, Jinhui
    Pan, Dabo
    He, Zhendan
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 713 - 725
  • [2] Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening
    Zhang, Feng-cai
    Sun, Zhong-ya
    Liao, Li-ping
    Zuo, Yu
    Zhang, Dan
    Wang, Jun
    Chen, Yan-tao
    Xiao, Sen-hao
    Jiang, Hao
    Lu, Tian
    Xu, Pan
    Yue, Li-yan
    Du, Dao-hai
    Zhang, Hao
    Liu, Chuan-peng
    Luo, Cheng
    [J]. ACTA PHARMACOLOGICA SINICA, 2020, 41 (02) : 286 - 292
  • [3] Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening
    Feng-cai Zhang
    Zhong-ya Sun
    Li-ping Liao
    Yu Zuo
    Dan Zhang
    Jun Wang
    Yan-tao Chen
    Sen-hao Xiao
    Hao Jiang
    Tian Lu
    Pan Xu
    Li-yan Yue
    Dao-hai Du
    Hao Zhang
    Chuan-peng Liu
    Cheng Luo
    [J]. Acta Pharmacologica Sinica, 2020, 41 : 286 - 292
  • [4] Discovery of Novel Chemical Series of OXA-48 β-Lactamase Inhibitors by High-Throughput Screening
    Garofalo, Barbara
    Prati, Federica
    Buonfiglio, Rosa
    Coletta, Isabella
    D'Atanasio, Noemi
    Molteni, Angela
    Carettoni, Daniele
    Wanke, Valeria
    Pochetti, Giorgio
    Montanari, Roberta
    Capelli, Davide
    Milanese, Claudio
    Di Giorgio, Francesco Paolo
    Ombrato, Rosella
    [J]. PHARMACEUTICALS, 2021, 14 (07)
  • [5] Discovery of 2-oxopiperazine dengue inhibitors by scaffold morphing of a phenotypic high-throughput screening hit
    Kounde, Cyrille S.
    Yeo, Hui-Quan
    Wang, Qing-Yin
    Wan, Kah Fei
    Dong, Hongping
    Karuna, Ratna
    Dix, Ina
    Wagner, Trixie
    Zou, Bin
    Simon, Oliver
    Bonamy, Ghislain M. C.
    Yeung, Bryan K. S.
    Yokokawa, Fumiaki
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (06) : 1385 - 1389
  • [6] The Discovery of Novel Protein Tyrosine Phosphatase ε Inhibitors Using a High-throughput Screening Approach
    Yun, Hye-Yeoung
    Ku, Bonsu
    Lee, Hye Seon
    Shin, Ho-Chul
    Park, Jun-Beom
    Kim, Chang Hyen
    Kim, Seung Jun
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2017, 38 (01) : 44 - 53
  • [7] Discovery of novel angiogenesis inhibitors using transgenic zebrafish as a high-throughput phenotypic screening model
    Min, Jaeki
    Kurtkaya, Serdar
    Sneed, Blossom
    Du, Yuhong
    Sandberg, Eric M.
    Baranowski, Timothy C.
    Sun, Aiming
    Snyder, James P.
    Liotta, Dennis C.
    Dingledine, Raymond
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [8] Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms
    Qian, J
    Voorbach, MJ
    Huth, JR
    Coen, ML
    Zhang, HC
    Ng, SC
    Comess, KM
    Petros, AM
    Rosenberg, SH
    Warrior, U
    Burns, DJ
    [J]. ANALYTICAL BIOCHEMISTRY, 2004, 328 (02) : 131 - 138
  • [9] High-Throughput Screening for Novel Inhibitors of Neisseria gonorrhoeae Penicillin-Binding Protein 2
    Fedarovich, Alena
    Djordjevic, Kevin A.
    Swanson, Shauna M.
    Peterson, Yuri K.
    Nicholas, Robert A.
    Davies, Christopher
    [J]. PLOS ONE, 2012, 7 (09):
  • [10] Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening
    Mok, N. Yi
    Chadwick, James
    Kellett, Katherine A. B.
    Hooper, Nigel M.
    Johnson, A. Peter
    Fishwick, Colin W. G.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6770 - 6774